Study of Azvudine Tablets Compared to TAF and IFN -2a for Treating Chronic Hepatitis B in Adults Aged 18 to 65

What This Trial Is About

Researchers are studying the long-term effects of Azvudine tablets in patients with chronic hepatitis B, a liver infection caused by the hepatitis B virus HBV. This trial compares Azvudine with two other treatments, TAF and IFN alpha-2a, to evaluate their ability to control HBV through a combination of antiviral action and immune system activation. The study aims to find a new treatment option that may help achieve clinical cure in chronic hepatitis B patients aged 18 to 65 years. Participants are randomly assigned to one of three groups receiving either Azvudine, TAF, or IFN alpha-2a treatment. The study is conducted as a phase 3 clinical trial with a single masking approach to monitor effects without bias. Patients receive their assigned treatment and are followed closely to compare how well each therapy controls the virus and impacts immune activity. During the 12-month follow-up period, researchers will regularly monitor patients viral load, liver function, and immune cell activity to assess treatment effectiveness. They will also track any adverse events for up to 30 days after confirmed chronic hepatitis B diagnosis. This detailed monitoring helps ensure participant safety and provides comprehensive data on the treatments long-term impact.

A Small Sample Prospective Clinical Study of Azvudine Tablets to Promote Clinical Cure in Patients With Chronic Hepatitis B